Sign in

    Charles Ndiaye

    Biotech Equity Research Associate at Stifel Financial Corp.

    Charles Ndiaye is a Biotech Equity Research Associate at Stifel Financial Corp., specializing in the analysis of biotechnology companies with a focus on delivering strategic insights for investment decisions. He supports coverage of innovative biotech firms, contributing to research on companies developing novel therapeutics and technologies, though detailed performance metrics and specific rankings are not publicly disclosed. Ndiaye began his equity research career at Stifel and has continued to build industry expertise in the biotechnology sector as of 2024. He maintains professional credentials as a registered representative, holding FINRA Series 7 and Series 63 licenses.

    Charles Ndiaye's questions to Travere Therapeutics (TVTX) leadership

    Charles Ndiaye's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    Charles Ndiaye from Stifel Financial Corp. asked about the company's current expectations for the Loss of Exclusivity (LOE) timeline for sparsentan in IgAN and how those expectations might change.

    Answer

    President and CEO Dr. Eric Dube stated that the company's current base planning assumption for LOE is into 2033. He also noted that the full approval in IgAN granted an additional term of orphan drug exclusivity through September 2031, providing another layer of protection.

    Ask Fintool Equity Research AI